Gilles de la Tourette syndrome: Patient's knowledge and concern of adverse effects
Identifieur interne : 003420 ( Main/Curation ); précédent : 003419; suivant : 003421Gilles de la Tourette syndrome: Patient's knowledge and concern of adverse effects
Auteurs : Katie Kompoliti [États-Unis] ; Christopher G. Goetz [États-Unis] ; Mary Morrissey [États-Unis] ; Sue Leurgans [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2006-02.
Descripteurs français
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Adolescent, Adult, Antipsychotic Agents (adverse effects), Antipsychotic Agents (therapeutic use), Awareness, Brain (drug effects), Child, Child, Preschool, Cohort Studies, Comorbidity, Dopamine, Dyskinesia, Gilles de la Tourette syndrome, Health Knowledge, Attitudes, Practice, Human, Humans, Nervous system diseases, Neuroleptic, Patient Education as Topic, Questionnaires, Tic, Tourette Syndrome (diagnosis), Toxicity, dopamine blockers, neuroleptics, tardive dyskinesia, tics, toxicity.
- MESH :
- chemical , adverse effects : Antipsychotic Agents.
- chemical , therapeutic use : Antipsychotic Agents.
- diagnosis : Tourette Syndrome.
- drug effects : Brain.
- Adolescent, Adult, Awareness, Child, Child, Preschool, Cohort Studies, Comorbidity, Health Knowledge, Attitudes, Practice, Humans, Patient Education as Topic, Questionnaires.
Abstract
The objective of this study was to assess awareness and concern of neuroleptic (NL)‐induced side effects in Gilles de la Tourette syndrome (GTS) patients. Although NLs are effective tic suppressants, they can be associated with various side effects. Data on patient knowledge and concern about side effects can guide educational efforts. One hundred consecutive GTS patients or parents in a tertiary referral medical center responded to a standardized, in‐person questionnaire. They were given a list of 15 side effects and asked which could be ascribed to NLs (9) or not (6). Side effect concern was rated on a 0 (none) to 10 (extreme) scale. The mean age for the 100 patients was 19.4 ± 14 years; 55 had a history of NL use, and 45 were NL‐naive. Less than half the cohort met criteria for being well informed. Only one third of the listed NL side effects were accurately identified by at least 75% of the respondents. Patients with past or current NL treatment were more accurate in identifying NL side effects but less concerned about them than NL‐naive patients. The side effects of greatest concern were seizures, tardive dyskinesia, thinking and emotion disturbances, and cardiac irregularities. Overall, patient awareness of NL side effects is insufficient, and although past exposure to NLs enhances knowledge, it decreases concern. © 2005 Movement Disorder Society
Url:
DOI: 10.1002/mds.20680
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001C04
- to stream Istex, to step Curation: Pour aller vers cette notice dans l'étape Curation :001C04
- to stream Istex, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001E80
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002E77
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002E77
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002D11
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :001435
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :001435
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001435
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :004734
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :001C52
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :001069
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :001A84
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :004B79
Links to Exploration step
ISTEX:2D255853C3BEEE64669F67CBCF5C55BC26EA5770Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Gilles de la Tourette syndrome: Patient's knowledge and concern of adverse effects</title>
<author><name sortKey="Kompoliti, Katie" sort="Kompoliti, Katie" uniqKey="Kompoliti K" first="Katie" last="Kompoliti">Katie Kompoliti</name>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
</author>
<author><name sortKey="Morrissey, Mary" sort="Morrissey, Mary" uniqKey="Morrissey M" first="Mary" last="Morrissey">Mary Morrissey</name>
</author>
<author><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:2D255853C3BEEE64669F67CBCF5C55BC26EA5770</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.20680</idno>
<idno type="url">https://api.istex.fr/document/2D255853C3BEEE64669F67CBCF5C55BC26EA5770/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001C04</idno>
<idno type="wicri:Area/Istex/Curation">001C04</idno>
<idno type="wicri:Area/Istex/Checkpoint">001E80</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Kompoliti K:gilles:de:la</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16161137</idno>
<idno type="wicri:Area/PubMed/Corpus">002E77</idno>
<idno type="wicri:Area/PubMed/Curation">002E77</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002D11</idno>
<idno type="wicri:Area/Ncbi/Merge">001435</idno>
<idno type="wicri:Area/Ncbi/Curation">001435</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001435</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Kompoliti K:gilles:de:la</idno>
<idno type="wicri:Area/Main/Merge">004734</idno>
<idno type="wicri:source">INIST</idno>
<idno type="RBID">Pascal:06-0171953</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001C52</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001069</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001A84</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Kompoliti K:gilles:de:la</idno>
<idno type="wicri:Area/Main/Merge">004B79</idno>
<idno type="wicri:Area/Main/Curation">003420</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Gilles de la Tourette syndrome: Patient's knowledge and concern of adverse effects</title>
<author><name sortKey="Kompoliti, Katie" sort="Kompoliti, Katie" uniqKey="Kompoliti K" first="Katie" last="Kompoliti">Katie Kompoliti</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morrissey, Mary" sort="Morrissey, Mary" uniqKey="Morrissey M" first="Mary" last="Morrissey">Mary Morrissey</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-02">2006-02</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="248">248</biblScope>
<biblScope unit="page" to="252">252</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">2D255853C3BEEE64669F67CBCF5C55BC26EA5770</idno>
<idno type="DOI">10.1002/mds.20680</idno>
<idno type="ArticleID">MDS20680</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Antipsychotic Agents (adverse effects)</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Awareness</term>
<term>Brain (drug effects)</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Cohort Studies</term>
<term>Comorbidity</term>
<term>Dopamine</term>
<term>Dyskinesia</term>
<term>Gilles de la Tourette syndrome</term>
<term>Health Knowledge, Attitudes, Practice</term>
<term>Human</term>
<term>Humans</term>
<term>Nervous system diseases</term>
<term>Neuroleptic</term>
<term>Patient Education as Topic</term>
<term>Questionnaires</term>
<term>Tic</term>
<term>Tourette Syndrome (diagnosis)</term>
<term>Toxicity</term>
<term>dopamine blockers</term>
<term>neuroleptics</term>
<term>tardive dyskinesia</term>
<term>tics</term>
<term>toxicity</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Tourette Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Awareness</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Cohort Studies</term>
<term>Comorbidity</term>
<term>Health Knowledge, Attitudes, Practice</term>
<term>Humans</term>
<term>Patient Education as Topic</term>
<term>Questionnaires</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Dopamine</term>
<term>Dyskinésie</term>
<term>Gilles de la Tourette syndrome</term>
<term>Homme</term>
<term>Neuroleptique</term>
<term>Système nerveux pathologie</term>
<term>Tic</term>
<term>Toxicité</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objective of this study was to assess awareness and concern of neuroleptic (NL)‐induced side effects in Gilles de la Tourette syndrome (GTS) patients. Although NLs are effective tic suppressants, they can be associated with various side effects. Data on patient knowledge and concern about side effects can guide educational efforts. One hundred consecutive GTS patients or parents in a tertiary referral medical center responded to a standardized, in‐person questionnaire. They were given a list of 15 side effects and asked which could be ascribed to NLs (9) or not (6). Side effect concern was rated on a 0 (none) to 10 (extreme) scale. The mean age for the 100 patients was 19.4 ± 14 years; 55 had a history of NL use, and 45 were NL‐naive. Less than half the cohort met criteria for being well informed. Only one third of the listed NL side effects were accurately identified by at least 75% of the respondents. Patients with past or current NL treatment were more accurate in identifying NL side effects but less concerned about them than NL‐naive patients. The side effects of greatest concern were seizures, tardive dyskinesia, thinking and emotion disturbances, and cardiac irregularities. Overall, patient awareness of NL side effects is insufficient, and although past exposure to NLs enhances knowledge, it decreases concern. © 2005 Movement Disorder Society</div>
</front>
</TEI>
<double idat="0885-3185:2006:Kompoliti K:gilles:de:la"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Gilles de la tourette syndrome : Patient's knowledge and concern of adverse effects</title>
<author><name sortKey="Kompoliti, Katie" sort="Kompoliti, Katie" uniqKey="Kompoliti K" first="Katie" last="Kompoliti">Katie Kompoliti</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morrissey, Mary" sort="Morrissey, Mary" uniqKey="Morrissey M" first="Mary" last="Morrissey">Mary Morrissey</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">06-0171953</idno>
<date when="2006">2006</date>
<idno type="stanalyst">PASCAL 06-0171953 INIST</idno>
<idno type="RBID">Pascal:06-0171953</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">001C52</idno>
<idno type="wicri:Area/PascalFrancis/Curation">001069</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">001A84</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Kompoliti K:gilles:de:la</idno>
<idno type="wicri:Area/Main/Merge">004B79</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Gilles de la tourette syndrome : Patient's knowledge and concern of adverse effects</title>
<author><name sortKey="Kompoliti, Katie" sort="Kompoliti, Katie" uniqKey="Kompoliti K" first="Katie" last="Kompoliti">Katie Kompoliti</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morrissey, Mary" sort="Morrissey, Mary" uniqKey="Morrissey M" first="Mary" last="Morrissey">Mary Morrissey</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name>
<affiliation wicri:level="2"><inist:fA14 i1="01"><s1>Department of Neurological Sciences, Rush University Medical Center</s1>
<s2>Chicago, Illinois</s2>
<s3>USA</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>3 aut.</sZ>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>États-Unis</country>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2006">2006</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Dopamine</term>
<term>Dyskinesia</term>
<term>Gilles de la Tourette syndrome</term>
<term>Human</term>
<term>Nervous system diseases</term>
<term>Neuroleptic</term>
<term>Tic</term>
<term>Toxicity</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Système nerveux pathologie</term>
<term>Gilles de la Tourette syndrome</term>
<term>Tic</term>
<term>Dyskinésie</term>
<term>Homme</term>
<term>Dopamine</term>
<term>Neuroleptique</term>
<term>Toxicité</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objective of this study was to assess awareness and concern of neuroleptic (NL)-induced side effects in Gilles de la Tourette syndrome (GTS) patients. Although NLs are effective tic suppressants, they can be associated with various side effects. Data on patient knowledge and concern about side effects can guide educational efforts. One hundred consecutive GTS patients or parents in a tertiary referral medical center responded to a standardized, in-person questionnaire. They were given a list of 15 side effects and asked which could be ascribed to NLs (9) or not (6). Side effect concern was rated on a 0 (none) to 10 (extreme) scale. The mean age for the 100 patients was 19.4 ± 14 years; 55 had a history of NL use, and 45 were NL-naive. Less than half the cohort met criteria for being well informed. Only one third of the listed NL side effects were accurately identified by at least 75% of the respondents. Patients with past or current NL treatment were more accurate in identifying NL side effects but less concerned about them than NL-naive patients. The side effects of greatest concern were seizures, tardive dyskinesia, thinking and emotion disturbances, and cardiac irregularities. Overall, patient awareness of NL side effects is insufficient, and although past exposure to NLs enhances knowledge, it decreases concern.</div>
</front>
</TEI>
</INIST>
<ISTEX><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Gilles de la Tourette syndrome: Patient's knowledge and concern of adverse effects</title>
<author><name sortKey="Kompoliti, Katie" sort="Kompoliti, Katie" uniqKey="Kompoliti K" first="Katie" last="Kompoliti">Katie Kompoliti</name>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
</author>
<author><name sortKey="Morrissey, Mary" sort="Morrissey, Mary" uniqKey="Morrissey M" first="Mary" last="Morrissey">Mary Morrissey</name>
</author>
<author><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">ISTEX</idno>
<idno type="RBID">ISTEX:2D255853C3BEEE64669F67CBCF5C55BC26EA5770</idno>
<date when="2006" year="2006">2006</date>
<idno type="doi">10.1002/mds.20680</idno>
<idno type="url">https://api.istex.fr/document/2D255853C3BEEE64669F67CBCF5C55BC26EA5770/fulltext/pdf</idno>
<idno type="wicri:Area/Istex/Corpus">001C04</idno>
<idno type="wicri:Area/Istex/Curation">001C04</idno>
<idno type="wicri:Area/Istex/Checkpoint">001E80</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Kompoliti K:gilles:de:la</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:16161137</idno>
<idno type="wicri:Area/PubMed/Corpus">002E77</idno>
<idno type="wicri:Area/PubMed/Curation">002E77</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002D11</idno>
<idno type="wicri:Area/Ncbi/Merge">001435</idno>
<idno type="wicri:Area/Ncbi/Curation">001435</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">001435</idno>
<idno type="wicri:doubleKey">0885-3185:2006:Kompoliti K:gilles:de:la</idno>
<idno type="wicri:Area/Main/Merge">004734</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Gilles de la Tourette syndrome: Patient's knowledge and concern of adverse effects</title>
<author><name sortKey="Kompoliti, Katie" sort="Kompoliti, Katie" uniqKey="Kompoliti K" first="Katie" last="Kompoliti">Katie Kompoliti</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Goetz, Christopher G" sort="Goetz, Christopher G" uniqKey="Goetz C" first="Christopher G." last="Goetz">Christopher G. Goetz</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Morrissey, Mary" sort="Morrissey, Mary" uniqKey="Morrissey M" first="Mary" last="Morrissey">Mary Morrissey</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Leurgans, Sue" sort="Leurgans, Sue" uniqKey="Leurgans S" first="Sue" last="Leurgans">Sue Leurgans</name>
<affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country>
<wicri:regionArea>Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois</wicri:regionArea>
<placeName><region type="state">Illinois</region>
</placeName>
</affiliation>
</author>
</analytic>
<monogr></monogr>
<series><title level="j">Movement Disorders</title>
<title level="j" type="abbrev">Mov. Disord.</title>
<idno type="ISSN">0885-3185</idno>
<idno type="eISSN">1531-8257</idno>
<imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher>
<pubPlace>Hoboken</pubPlace>
<date type="published" when="2006-02">2006-02</date>
<biblScope unit="vol">21</biblScope>
<biblScope unit="issue">2</biblScope>
<biblScope unit="page" from="248">248</biblScope>
<biblScope unit="page" to="252">252</biblScope>
</imprint>
<idno type="ISSN">0885-3185</idno>
</series>
<idno type="istex">2D255853C3BEEE64669F67CBCF5C55BC26EA5770</idno>
<idno type="DOI">10.1002/mds.20680</idno>
<idno type="ArticleID">MDS20680</idno>
</biblStruct>
</sourceDesc>
<seriesStmt><idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Antipsychotic Agents (adverse effects)</term>
<term>Antipsychotic Agents (therapeutic use)</term>
<term>Awareness</term>
<term>Brain (drug effects)</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Cohort Studies</term>
<term>Comorbidity</term>
<term>Health Knowledge, Attitudes, Practice</term>
<term>Humans</term>
<term>Patient Education as Topic</term>
<term>Questionnaires</term>
<term>Tourette Syndrome (diagnosis)</term>
<term>dopamine blockers</term>
<term>neuroleptics</term>
<term>tardive dyskinesia</term>
<term>tics</term>
<term>toxicity</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Antipsychotic Agents</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Antipsychotic Agents</term>
</keywords>
<keywords scheme="MESH" qualifier="diagnosis" xml:lang="en"><term>Tourette Syndrome</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>Brain</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Adolescent</term>
<term>Adult</term>
<term>Awareness</term>
<term>Child</term>
<term>Child, Preschool</term>
<term>Cohort Studies</term>
<term>Comorbidity</term>
<term>Health Knowledge, Attitudes, Practice</term>
<term>Humans</term>
<term>Patient Education as Topic</term>
<term>Questionnaires</term>
</keywords>
</textClass>
<langUsage><language ident="en">en</language>
</langUsage>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">The objective of this study was to assess awareness and concern of neuroleptic (NL)‐induced side effects in Gilles de la Tourette syndrome (GTS) patients. Although NLs are effective tic suppressants, they can be associated with various side effects. Data on patient knowledge and concern about side effects can guide educational efforts. One hundred consecutive GTS patients or parents in a tertiary referral medical center responded to a standardized, in‐person questionnaire. They were given a list of 15 side effects and asked which could be ascribed to NLs (9) or not (6). Side effect concern was rated on a 0 (none) to 10 (extreme) scale. The mean age for the 100 patients was 19.4 ± 14 years; 55 had a history of NL use, and 45 were NL‐naive. Less than half the cohort met criteria for being well informed. Only one third of the listed NL side effects were accurately identified by at least 75% of the respondents. Patients with past or current NL treatment were more accurate in identifying NL side effects but less concerned about them than NL‐naive patients. The side effects of greatest concern were seizures, tardive dyskinesia, thinking and emotion disturbances, and cardiac irregularities. Overall, patient awareness of NL side effects is insufficient, and although past exposure to NLs enhances knowledge, it decreases concern. © 2005 Movement Disorder Society</div>
</front>
</TEI>
</ISTEX>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003420 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 003420 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Wicri/Santé |area= MovDisordV3 |flux= Main |étape= Curation |type= RBID |clé= ISTEX:2D255853C3BEEE64669F67CBCF5C55BC26EA5770 |texte= Gilles de la Tourette syndrome: Patient's knowledge and concern of adverse effects }}
![]() | This area was generated with Dilib version V0.6.23. | ![]() |